首页 | 本学科首页   官方微博 | 高级检索  
     


Benefit of Antihypertensive Treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) Trial
Authors:Jerzy Gasowski  Willem H. Birkenhäger  Jan A. Staessen  Peter W. de Leeuw
Affiliation:(1) Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium;(2) Erasmus University Rotterdam, The Netherlands;(3) Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium;(4) Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands
Abstract:In this review we attempt to determine the role of calcium channel blockers in preventing cardiovascular sequelae in patients with both hypertension and diabetes mellitus. The data have been collected from three sources: post-hoc analyses of subgroups of diabetic patients in placebo-controlled hypertension trials (SHEP, Syst-Eur, Syst-China); stepped-care blood pressure-oriented trials (HOT, UKPDS); and comparative trials focusing primarily on metabolic aspects and intermediate endpoints (ABCD, FACET).On balance, the data seem to indicate that long-acting calcium channel blockers score remarkably well in preventing cardiovascular complications in diabetic hypertensive patients.
Keywords:hypertension  diabetes  prospective antihypertensive trials  trial endpoints  dihydropiridine-type long-acting calcium channel blockers  ACE inhibitors  diuretics  beta-blockers
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号